Kyverna Therapeutics, Inc. KYTX Total debt

Total debt at other companies

Bristol-Myers SquibbBMY

$43.33B-12.3%

Gilead SciencesGILD

$26.25B+5.2%

Climb Bio, Inc.CLYM

$479K+1.1%

Artiva Biotherapeutics, Inc.ARTV

$9.85M-25.5%

Iovance Biotherapeutics, Inc.IOVA

$46M-11.8%

Allogene TherapeuticsALLO

$81.05M-8.9%

FAQ

What is Kyverna Therapeutics, Inc.'s total debt?

Kyverna Therapeutics, Inc. (KYTX) reported total debt of $9.16M in Q1 2026.

How has Kyverna Therapeutics, Inc.'s total debt changed year-over-year?

Kyverna Therapeutics, Inc.'s total debt increased by 32.1% year-over-year, from $6.94M to $9.16M.

What is the long-term trend for Kyverna Therapeutics, Inc.'s total debt?

Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s total debt has grown at a -28.9% compound annual growth rate (CAGR), from $9.08M to $4.6M.

What does total debt mean?

Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.